Free Trial
→ From Social Security to Social Prosperity? (From Paradigm Press) (Ad)
NASDAQ:MGRX

Mangoceuticals 7/28/2023 Earnings Report

Mangoceuticals logo
$1.81 -0.29 (-13.81%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.81 0.00 (0.00%)
As of 04/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings History

Mangoceuticals EPS Results

Actual EPS
-$31.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mangoceuticals Revenue Results

Actual Revenue
$0.14 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mangoceuticals Announcement Details

Quarter
Date
7/28/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Mangoceuticals' Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Mangoceuticals Earnings Headlines

Mangoceuticals Acquires IP to Expand Product Line
April 25 at 9:40 AM | tipranks.com
Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
April 25 at 9:00 AM | globenewswire.com
From Social Security to Social Prosperity?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
April 26, 2025 | Paradigm Press (Ad)
Mangoceuticals Is Reengineering the Self-Care Blueprint with Better Personal Health and Wellness Solutions
April 24 at 2:39 PM | finance.yahoo.com
Mangoceuticals Issues Bonus Shares to Leadership
April 11, 2025 | tipranks.com
Mangoceuticals Issues Common Stock in Exchange for Preferred
March 30, 2025 | investing.com
See More Mangoceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email.

About Mangoceuticals

Mangoceuticals (NASDAQ:MGRX) develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

View Mangoceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles